Meniere’s Disease - Pipeline Insight, 2021
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Meniere’s Disease - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Meniere’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Meniere’s Disease: Overview
Meniere’s disease is a chronic condition that affects the inner ear. The disease is characterized by episodic vertigo attacks, fluctuating hearing loss that becomes permanent over time, tinnitus, and a feeling of ear fullness. The cause of Meniere's disease is unknown. Meniere’s disease usually affects only one ear. Attacks of dizziness may come on suddenly or after a short period of tinnitus or muffled hearing. Some people will have single attacks of dizziness separated by long periods of time. People with Meniere's can experience a feeling of pressure in the ear, sudden dizzy spells, tinnitus, muffled hearing or hearing loss. The symptoms of Meniere’s disease are caused by the buildup of fluid in the compartments of the inner ear, called the labyrinth. Although Meniere's disease can affect people of any age, people in their 40s and 50s are much more likely to experience it. A series of diagnostic tests can be done to check the balance and hearing. These include: Audiometric exam, electronystagmogram, electrocochleography, and auditory brainstem response test among others. No cure exists for Meniere's disease. A number of treatments can help reduce the severity and frequency of vertigo episodes.
'Meniere’s Disease - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Meniere’s Disease pipeline landscape is provided which includes the disease overview and Meniere’s Disease treatment guidelines. The assessment part of the report embraces, in depth Meniere’s Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Meniere’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Meniere’s Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Meniere’s Disease Emerging Drugs
Further product details are provided in the report……..
Meniere’s Disease: Therapeutic Assessment
This segment of the report provides insights about the different Meniere’s Disease drugs segregated based on following parameters that define the scope of the report, such as:
Meniere’s Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Meniere’s Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Meniere’s Disease drugs.
Meniere’s Disease Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Meniere’s Disease - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Meniere’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Meniere’s Disease: Overview
Meniere’s disease is a chronic condition that affects the inner ear. The disease is characterized by episodic vertigo attacks, fluctuating hearing loss that becomes permanent over time, tinnitus, and a feeling of ear fullness. The cause of Meniere's disease is unknown. Meniere’s disease usually affects only one ear. Attacks of dizziness may come on suddenly or after a short period of tinnitus or muffled hearing. Some people will have single attacks of dizziness separated by long periods of time. People with Meniere's can experience a feeling of pressure in the ear, sudden dizzy spells, tinnitus, muffled hearing or hearing loss. The symptoms of Meniere’s disease are caused by the buildup of fluid in the compartments of the inner ear, called the labyrinth. Although Meniere's disease can affect people of any age, people in their 40s and 50s are much more likely to experience it. A series of diagnostic tests can be done to check the balance and hearing. These include: Audiometric exam, electronystagmogram, electrocochleography, and auditory brainstem response test among others. No cure exists for Meniere's disease. A number of treatments can help reduce the severity and frequency of vertigo episodes.
'Meniere’s Disease - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Meniere’s Disease pipeline landscape is provided which includes the disease overview and Meniere’s Disease treatment guidelines. The assessment part of the report embraces, in depth Meniere’s Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Meniere’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Meniere’s Disease R&D. The therapies under development are focused on novel approaches to treat/improve Meniere’s Disease.
This segment of the Meniere’s Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Meniere’s Disease Emerging Drugs
- OTIVIDEX: Otonomy
- SPI-1005: Sound Pharmaceuticals
Further product details are provided in the report……..
Meniere’s Disease: Therapeutic Assessment
This segment of the report provides insights about the different Meniere’s Disease drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Meniere’s Disease
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Meniere’s Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Meniere’s Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Meniere’s Disease drugs.
Meniere’s Disease Report Insights
- Meniere’s Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Meniere’s Disease drugs?
- How many Meniere’s Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Meniere’s Disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Meniere’s Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Meniere’s Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
- Otonomy
- Synphora
- Sound Pharmaceuticals
- Auris Medical
- Apsen Farmaceutica
- Orbis Biosciences
- Quark Pharmaceuticals
- OTIVIDEX
- Latanoprost intratympanic
- SPI-1005
- Betahistine intranasal
- APSLXR
- ORB 202
- QPI-1017
Introduction
Executive Summary
Meniere’s Disease: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Meniere’s Disease – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Meniere’s Disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Meniere’s Disease Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
OTIVIDEX: Otonomy
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
Betahistine intranasal: Auris Medical
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
• Comparative Analysis
APSLXR: Apsen Farmaceutica
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Meniere’s Disease Key Companies
Meniere’s Disease Key Products
Meniere’s Disease- Unmet Needs
Meniere’s Disease- Market Drivers and Barriers
Meniere’s Disease- Future Perspectives and Conclusion
Meniere’s Disease Analyst Views
Meniere’s Disease Key Companies
Appendix
Executive Summary
Meniere’s Disease: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Meniere’s Disease – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Meniere’s Disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Meniere’s Disease Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
OTIVIDEX: Otonomy
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
Betahistine intranasal: Auris Medical
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
• Comparative Analysis
APSLXR: Apsen Farmaceutica
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Meniere’s Disease Key Companies
Meniere’s Disease Key Products
Meniere’s Disease- Unmet Needs
Meniere’s Disease- Market Drivers and Barriers
Meniere’s Disease- Future Perspectives and Conclusion
Meniere’s Disease Analyst Views
Meniere’s Disease Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Meniere’s Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Meniere’s Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Meniere’s Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Meniere’s Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products